PlainPill

Tirzepatide

Also known as Mounjaro, Zepbound

The short answer. Most people who report on Tirzepatide say it helped (75% of 287). It is most often used for weight loss: 94% of 206 reports say that improved. It is well studied — 214 meta-analyses on PubMed. The most common complaint is nausea.

What users report
75%helped287 reports · high confidence
214 helped60 mixed13 didn't help

From 428 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
214
meta-analyses
132
RCTs
2,569
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Tirzepatide does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 214 meta-analyses on PubMed ↗ · 132 randomized trials ↗

Diabetologia · 2024 · Meta-analysis / systematic review
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Conclusion: Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.

PubMed 38613667 ↗
Obes Rev · 2025 · Meta-analysis / systematic review
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis

Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.

PubMed 40186344 ↗
Registered clinical trials

296 human trials on ClinicalTrials.gov test Tirzepatide — 91 completed, 97 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance…”

Full label on DailyMed (NIH) ↗

FDA recalls

21 recalls of products named for Tirzepatide. Most recent:

  • 2026-03-11 · Class II: Lack of Assurance of Sterility record ↗
  • 2025-11-05 · Class II: Lack of Assurance of Sterility record ↗
  • 2025-10-15 · Class II: Lack of Assurance of Sterility record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

160,663 adverse-event reports mention Tirzepatide. Most often reported:

  • Incorrect dose administered · 29,672
  • Nausea · 17,092
  • Injection site pain · 13,906
  • Diarrhoea · 10,006
  • Extra dose administered · 9,608
  • Off label use · 8,941

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Tirzepatide C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 8 research projects with Tirzepatide in the title, $7,874,070 in total (2024–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Tirzepatide injection ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

nausea ×17fatigue ×16anhedonia ×8constipation ×8stomach issues ×8appetite suppression ×5insomnia ×1sexual side ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“Tirzepatide works so well! Do some research in the r/peptides subreddit and the r/tirzepatide subreddit. It's the most effective thing I've ever seen for appetite suppressant.”
HelpedRead the discussion ↗
“I’m currently on tirzepatide 7.5mg (midway dose). Stacking sema because tirz isn’t helping it’s serious insomnia and sexual side effects.”
Didn't helpRead the discussion ↗
“The Tirz was amazing and I dropped to a maintenance dose after I hit 195. When I stopped all peptides for two weeks prior to surgery, the Tirz didnt do anything when I restarted.”
MixedRead the discussion ↗
“mounjaro has been the best. I lost like 15 pounds in two months on this thing.”
HelpedRead the discussion ↗
Read more Tirzepatide reviews →
Top discussions (5)

Tirzepatide compared

Other options for weight loss

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate